AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03120377 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Platform sham
Description: will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
Study NCT03670784 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, epidemiological investigation
Study NCT02515201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine
Description: taurolidine in central catheter lumen
Study NCT02515201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: heparin in central venous catheter lumen
Study NCT03462186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthfinder invitation
Description: Invitation to use healthfinder (healthfinder.gov/myhealthfinder
Study NCT01778920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17 imaging contrast agent
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Study NCT00443781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: functional anesthetic discography
Description: Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
Study NCT00443781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: provocative discography
Description: Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain.
Study NCT00678548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant guided imagery
Description: CD with pleasant guided imagery
Study NCT00678548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain diary
Description: Filling out a pain diary
Study NCT02475616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Study NCT02475616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02767739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical, social and cultural activities
Description: This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
Study NCT04023617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
Study NCT04023617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
Study NCT00430937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 4 mg/kg intravenous once daily
Study NCT00430937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 1 g intravenous twice daily
Study NCT00430937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: 400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
Study NCT01777945 — intervention group
Intervention type: DRUG
Intervention: capecitabine
Description: Participants received capecitabine according to individualized physician-prescribed regimen.
Study NCT01777945 — intervention group
Intervention type: DRUG
Intervention: docetaxel
Description: Participants received docetaxel according to individualized physician-prescribed regimens.
Study NCT03623061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: F-Point
Description: F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
Study NCT01072825 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
Study NCT01072825 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
Study NCT01072825 — intervention group
Intervention type: OTHER
Intervention: clinical evaluation
Description: height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
Study NCT01072825 — intervention group
Intervention type: OTHER
Intervention: Dermatology evaluation
Description: Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
Study NCT01072825 — intervention group
Intervention type: OTHER
Intervention: Bone evaluation
Description: PQCT scanner, BMD assessment
Study NCT01659255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally
Study NCT03929861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (BAYT006267) 150 mg capsules
Description: Fluconazole 150 mg
Study NCT03929861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg capsules (DiflucanTM)
Description: Fluconazole 150 mg
Study NCT00790881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether/Lumefantrine
Description: Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
Study NCT00790881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/ lumefantrine
Description: Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
Study NCT03724409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90]Y-DOTATOC
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
Study NCT02155647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Study NCT02530450 — intervention group
Intervention type: DEVICE
Intervention: continuous glucose monitoring (CGM)
Description: All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00374296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 administered orally three-times per week
Study NCT05492565 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
Study NCT01277952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Brain pace maker, implanted in the brain
Study NCT01085799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
Study NCT02158390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jasper-EMT with words and AAC
Description: Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months.
Study NCT01760512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Gastric bypass
Study NCT01760512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Description: Gastric bypass
Study NCT01522365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abutment-supported XiVE CAD/CAM bridge
Description: One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
Study NCT01522365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant-supported XiVE CAD/CAM bridge
Description: One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
Study NCT01824407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrohydraulic-generated shock wave
Study NCT01824407 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device plus standard of care
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02400281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT02519777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Study NCT02519777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Study NCT02519777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dolutegravir (DTG)
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Study NCT02519777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Study NCT02519777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Study NCT03661658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using short dental implant
Description: Using short dental implant for patients with atrophic posterior mandible.
Study NCT03661658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve lateralization with simultaneous implant placement
Description: Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
Study NCT03474172 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cloak Shape Device for Sham Tuina
Description: The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
Study NCT03474172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloak Shape Device for Genuine Tuina
Description: The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
Study NCT03421236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ty21a
Description: intravesical administration of Ty21a
Study NCT02092766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Study NCT02092766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinine
Study NCT01862367 — intervention group
Intervention type: DRUG
Intervention: catridecacog
Description: No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
Study NCT00885781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid emulsion for TPN
Description: 1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
Study NCT00885781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipid emulsion for TPN
Description: 1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
Study NCT02789891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy including No. 14v
Description: After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
Study NCT02789891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy excluding No. 14v
Description: After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
Study NCT02239614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV 4 µg + alum adjuvant
Description: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
Study NCT01331967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15-30mg, once daily for 9 months
Study NCT03429257 — intervention group
Intervention type: OTHER
Intervention: Exposures of interest: Maternal EED and Aflatoxin Exposure
Description: Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
Study NCT04955418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epi-No®
Description: evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
Study NCT04955418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation
Description: evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
Study NCT04955418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation
Description: evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
Study NCT02207257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of edoxaban-induced anticoagulation
Study NCT02207257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of edoxaban-induced anticoagulation
Study NCT02207257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Study NCT01344187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin solution
Description: 0.12% riboflavin ophthalmic solution
Study NCT01344187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 0.0% riboflavin ophthalmic solution
Study NCT01344187 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KXL System
Description: 30 mW/cm2
Study NCT01344187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL System
Description: 30 mW/cm2
Study NCT02963337 — intervention group
Intervention type: DRUG
Intervention: remifentanil
Description: Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
Study NCT02963337 — intervention group
Intervention type: DRUG
Intervention: combined spinal-epidural analgesia
Description: Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
Study NCT00281684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB705498 400 mg
Description: SB705498 400 mg
Study NCT00281684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB705498 1000 mg
Description: SB705498 1000 mg
Study NCT00281684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00281684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Codamol
Description: Co-Codamol
Study NCT03667365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aortic valve replacement
Description: aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
Study NCT03667365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strict clinical surveillance
Description: strict clinical surveillance strategy
Study NCT02751515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bain De Soliel - Solid
Description: 0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
Study NCT02751515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT02177279 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visit A high wheat bran
Study NCT02177279 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visit B normal wheat bran
Study NCT02177279 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow up normal (8days) and high (1day) bran consumption
Study NCT04476979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
Study NCT04476979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
Study NCT04476979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
Study NCT04535895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost
Description: Adjuvant breast cancer irradiation including simultaneous integrated boost
Study NCT02467569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay020
Study NCT01112852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoloc 40 mg
Description: pantoloc iv. infusion per day
Study NCT01112852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatostatin or terlipressin
Description: Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.